Table 2.
Time of interval to surgery, postoperative chemotherapy, overall survival, and median survival time.
| Year | References | Interval between chemotherapy and surgery | Postoperative chemotherapy | OS (rate) | MST (months) | ||||
|---|---|---|---|---|---|---|---|---|---|
| CHT | CHT + surgery | CHT | CHT + surgery | ||||||
| R1/R2 | R0 | R1/R2 | R0 | ||||||
| 1997 | Nakajima et al. (35) | NS | NS | 5-yr (55.6%) | 4.7 | 6.5 | |||
| 2002 | Yano et al. (36) | NS | NS | ||||||
| 2012 | Satoh et al. (15) | 2–4 weeks | Yes | 2-yr (12%) | 2-yr (75.0%)* | 19.2 | |||
| 2012 | Kanda et al. (16) | 130 (59–391) days | Yes | 3-yr (0%) | 3-yr (49.5%) | 29 | |||
| 2013 | Han et al. (37) | 1.3 (0.3–2.3) months | Yes | 3-yr (41.4%) | 7.8 | 22.9 | |||
| 2014 | Kim et al. (38) | 5.6 (2–12) months | Yes | 3-yr (0%) | 3-yr (0%) | 3-yr (50%) 5-yr (40%) | 8 | 18 | 37 |
| 2014 | Saito et al. (39) | 4–6 weeks | Yes | 3-yr (53.8%) | 53 | ||||
| 2015 | Fukuchi et al. (22) | 6 weeks | Yes | 5-yr (1%) | 5-yr (15%) | 5-yr (49%) | 14 | 30 | 62 |
| 2015 | Kinoshita et al. (40) | 85 (43–414) days | Yes | 3-yr (0%) | 3-yr (16%) | 3-yr (50.1%) | 9.6 | 15.6 | 29.9 |
| 2017 | Sato et al. (41) | 5–6 weeks | Yes | 5-yr (0%) | 5-yr (0%) | 5-yr (48.6%) | 15.7 | 21.7 | 47.9 |
| 2017 | Mieno et al. (42) | 36 (4–70)days | Yes | 3-yr (73.1%) | |||||
| 2017 | Uemura (43) | NS | NS | 13.7 | 24 | ||||
| 2017 | Einama et al. (44) | 5–6 weeks | Yes | 29 | |||||
| 2017 | Maeda et al. (45) | NS | Yes | 2-yr (100%) | |||||
| 2017 | Yamaguchi et al. (46) | 126 days* | Yes | 11.3 | 21.2 | 41.3 | |||
| 2017 | AIO-FLOT3 (29) | 3 weeks | Yes | 15.9 | |||||
| 2018 | Morgagni et al. (47) | NS | NS | 3-yr (0%) | 3-yr (39.4%) | 38 | |||
| 2018 | Beom et al. (32) | 24 weeks | Yes | ||||||
| 2019 | Solaini et al. (48) | 3–6 months | Yes | ||||||
| 2019 | Li et al. (49) | NS | Yes | 10.9 | |||||
OS, Overall survival; MST, Median survival time; CHT, Chemotherapy;
*
R0 in only pre-Cy1 patients;
**Data from consultation with authors by email.